http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
초격자 고경도 나노 다층막 소재의 복합경도 해석을 통한 계면 강화 효과 분석
김성훈,이윤희,박종극,백영준,권동일 대한금속재료학회 2003 대한금속·재료학회지 Vol.41 No.12
Multilayer coatings consisting of very thin layers of nitride materials deposited by magnetron sputtering (sometimes called superlattices) exhibit hardnesses over 50 GPa, much higher than that of single layers. Several explanations for this hardness increase have been proposed, including dislocation blocking by layer interfaces, Hall- Petch strengthening, strain effects at layer interfaces, and the supermodulus effect. Among these, dislocation blocking has been generally accepted as a dominant factor in large hardness enhancement. However, the interface between two materials consisting of multilayers is broadened due to interdiffusion. The magnitude of hardness enhancement by the interface has not yet been quantified for real systems. In this study, the concept of composite hardness is introduced to quantify the interface-related hardness enhancement. We suggest a composite hardness equation and quantifythe magnitude of hardness increase by using an equation based on the interface hardness and the interface thickness derived by comparing results derived from this equation and those determined in nanoindentation tests. Three multilayer systems, such as TiN/VN, TiN/NbN and CrN/NbN were used in the equation.
Jong-Il Park,Young-Guk Ko,Seung-Jun Lee,Chul-Min Ahn,Seung-Woon Rha,Cheol-Woong Yu,Jong Kwan Park,Sang-Ho Park,Jae-Hwan Lee,Su-Hong Kim,Yong-Joon Lee,Sung-Jin Hong,Jung-Sun Kim,Byeong-Keuk Kim,Myeong- The Korean Society of Cardiology 2024 Korean Circulation Journal Vol.54 No.2
Background and Objectives: The popliteal artery is generally regarded as a "no-stent zone." Limited data are available on the outcomes of drug-coated balloons (DCBs) for popliteal artery disease. This study aimed to evaluate the 12-month clinical outcomes among patients who received DCB treatment for atherosclerotic popliteal artery disease. Methods: This prospective, multicenter registry study enrolled 100 patients from 7 Korean endovascular centers who underwent endovascular therapy using IN.PACT DCB (Medtronic) for symptomatic atherosclerotic popliteal artery disease. The primary endpoint was 12-month clinical primary patency and the secondary endpoint was clinically driven target lesion revascularization (TLR)-free rate. Results: The mean age of the study cohort was 65.7±10.8 years, and 77% of enrolled patients were men. The mean lesion length was 93.7±53.7 mm, and total occlusions were present in 45% of patients. Technical success was achieved in all patients. Combined atherectomy was performed in 17% and provisional stenting was required in 11%. Out of the enrolled patients, 91 patients completed the 12-month follow-up. Clinical primary patency and TLR-free survival rates at 12 months were 76.0% and 87.2%, respectively. A multivariate Cox regression analysis identified female and longer lesion length as the significant independent predictors of loss of patency. Conclusions: DCB treatment yielded favorable 12-month clinical primary patency and TLR-free survival outcomes in patients with popliteal artery disease.
Jong-Il Park,Young-Guk Ko,Seung-Jun Lee,Chul-Min Ahn,Seung-Woon Rha,Cheol-Woong Yu,Jong Kwan Park,Sang-Ho Park,Jae-Hwan Lee,Su-Hong Kim,Yong-Joon Lee,Sung-Jin Hong,Jung-Sun Kim,Byeong-Keuk Kim,Myeong- 대한심장학회 2024 Korean Circulation Journal Vol.54 No.8
Background and Objectives: The popliteal artery is generally regarded as a “no-stent zone”. Limited data are available on the outcomes of drug-coated balloons (DCBs) for popliteal artery disease. This study aimed to evaluate the 12-month clinical outcomes among patients who received DCB treatment for atherosclerotic popliteal artery disease. Methods: This prospective, multicenter registry study enrolled 100 patients from 7 Korean endovascular centers who underwent endovascular therapy using IN.PACT DCB (Medtronic) for symptomatic atherosclerotic popliteal artery disease. The primary endpoint was 12-month clinical primary patency and the secondary endpoint was clinically driven target lesion revascularization (TLR)–free rate. Results: The mean age of the study cohort was 65.7±10.8 years, and 77% of enrolled patients were men. The mean lesion length was 93.7±53.7 mm, and total occlusions were present in 45% of patients. Technical success was achieved in all patients. Combined atherectomy was performed in 17% and provisional stenting was required in 11%. Out of the enrolled patients, 91 patients completed the 12-month follow-up. Clinical primary patency and TLR-free survival rates at 12 months were 76.0% and 87.2%, respectively. A multivariate Cox regression analysis identified female and longer lesion length as the significant independent predictors of loss of patency. Conclusions: DCB treatment yielded favorable 12-month clinical primary patency and TLR-free survival outcomes in patients with popliteal artery disease.
Lee, Shin-Hwa,Chang, Hun Soo,Jang, An-Soo,Park, Sung-Woo,Park, Jong Sook,Uh, Soo-Taek,Kim, Yong Hoon,Oh, Bermseok,Lee, Jong-Keuk,Park, Byung-Lae,Shin, Hyung Doo,Park, Choon-Sik,Kimm, Kuchan Published for the Galton Laboratory by Cambridge U 2011 Annals of human genetics Vol.75 No.3
<P>Asthma manifests as TH2-dominant airway inflammation regulated by inducible T-cell kinase (ITK). To investigate associations between genetic variants of the ITK gene and asthma, 31 single-nucleotide polymorphisms (SNPs) were genotyped in 303 normal controls and 498 asthmatics and the two groups were compared using logistic regression models. The functional effects of the ITK promoter SNP were assessed using pGL3 luciferase reporter systems and gel-shift assays. The minor allele-196C>T in the promoter region of the ITK gene was significantly more frequent in asthmatics than in controls. The luciferase activity of the PGL3-ITK-196T allele construct was higher than that of the -196C allele. In the gel-shift assay, -196T double-stranded oligonucleotides bound more strongly to Jurkat cell nuclear protein compared to the -196C double-stranded oligonucleotides. People with the -rare allele 196C>T may be more susceptible to asthma via transcriptional regulation of the ITK gene.</P>
PARK, Young Na,LEE, Youn Ju,CHOI, Jeon Hyeun,JIN, Meihua,YANG, Ju Hae,LI, Ying,LEE, Jiean,LI, Xian,KIM, Keuk-Jun,SON, Jong Keun,CHANG, Hyeun Wook,KIM, Jong Yeon,LEE, Eunkyung Japan Society for Bioscience, Biotechnology, and A 2011 Bioscience, Biotechnology, and Biochemistry Vol.75 No.5
<P>The flowers of <I>Inula japonica</I> (Inulae Flos) have long been used in traditional medicine for treating inflammatory diseases. The effects on OVA-induced asthmatic mice of an Inulae Flos extract (IFE) were evaluated in this study. The anti-asthmatic effects of IFE were determined by observing eosinophil recruitment, airway hyper-responsiveness (AHR), Th2 cytokine and IgE levels, and lung histopathology. The IFE treatment effectively reduced the percentage of eosinophils and Th2 cytokines in the bronchoalveolar lavage fluid (BALF) when compared to the levels in OVA-induced mice. IFE also suppressed AHR induced by aerosolized methacholine in OVA-induced mice. The results of the histopathological studies indicate that inflammatory cell infiltration and mucus hypersecretion were both inhibited by the IFE administration when compared to the effect on OVA-induced mice. The IFE treatment also suppressed the serum IgE levels and decreased Th2 cytokines in the supernatant of cultured splenocytes. These results suggest that IFE may have therapeutic potential against asthma.</P>
Association of the X-linked Androgen Receptor Leu57Gln Polymorphism with Monomelic Amyotrophy
Park, Young-Mi,Lim, Young-Min,Kim, Dae-Seong,Lee, Jong-Keuk,Kim, Kwang-Kuk Korea Genome Organization 2011 Genomics & informatics Vol.9 No.2
Monomelic amyotrophy (MA), also known as Hirayama disease, occurs mainly in young men and manifests as weakness and wasting of the muscles of the distal upper limbs. Here, we sought to identify a genetic basis for MA. Given the predominance of MA in males, we focused on candidate neurological disease genes located on the X chromosome, selecting two X-linked candidate genes, androgen receptor (AR ) and ubiquitin-like modifier activating enzyme 1 (UBA1). Screening for genetic variants using patients' genomic DNA revealed three known genetic variants in the coding region of the AR gene: one nonsynonymous single-nucleotide polymorphism (SNP; rs78686797) encoding Leu57Gln, and two variants of polymorphic trinucleotide repeat segments that encode polyglutamine (CAG repeat; rs5902610) and polyglycine (GGC repeat; rs3138869) tracts. Notably, the Leu57Gln polymorphism was found in two patients with MA from 24 MA patients, whereas no variants were found in 142 healthy male controls. However, the numbers of CAG and GGC repeats in the AR gene were within the normal range. These data suggest that the Leu57Gln polymorphism encoded by the X-linked AR gene may contribute to the development of MA.